<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 311 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page310.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=311">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 311 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 311</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=311"><img src="../thumb/311.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>274 / 2020-04                                                            Anti-Microbials - 18.12
   Varicella zoster- immunocompromis.pts: Adults: 10 mg/kg   zole, monit.prothromb.time with concom. warfar.as coagulat.time   in combinat.with other antiretrovir. Agents. See prod.lit.for dos.
   8 hrly. Childr: 500 mg/m 8 hrly.  may incr./decr., alt.ther.to clarithromycin recom.in Mycobacterium   guidelines breakdown.
             2
   H simplex encephalit.-norm./ immunocomprom. pts: Adults:   avium-intracellular complex.  Contraindications: Pregn.& lactat., sev.liv.dis./ hepat. insuff.,
   10 mg/kg 8 hrly. Childr: 500 mg/m 8 hrly.  Drug interactions: Low.plasma conc.of concom. meds.metabol.  safety & effic.not est.in childr.und. 18 yrs., anti-TB regimens con-
                  2
   H simplex infects: Neonates: 10 mg/kg 8 hrly.  by CYP3A or CYP2B enzymes, saquinavir (hard gelatine caps) &   tain.rifampicin, Ritovavir is a potent inhibit.of many cytochrome
   Sev.immunocompromis.pts: Adults: Bone marrow recip.should   indinavir lev. reduc., incr.plasma lev.with ketoconazole, nevirapine   P450 mediat. biotransformats.& may prod.large incr. in plas-
   receive IV acyclovir 3xdly for 1 mnth prior to receiv.oral ther. Ther.  expos.incr.with concom.fluconazole, AUC, C max& C min signific.low.  ma conc.of meds.metabol.by cytochrome P450. Contraindicat.
   durat: 6 mnths & 12 mnths in advanc.HIV dis.  by rifampicin, rifabutin conc. signific.incr., hypericum perforatum   concom.meds.incl. alfuzosin/ amiodarone/bepridil/flecainide/
   Contraindications: Hypersens.to valaciclovir, safety & effic.in   (St John’s Wort) decr.conc.& result.sub-optimal lev., elev. trough   propafenone/quinidine/encainide/digoxin/voriconazole/astemi-
   pregn.& lactat.not est.      conc.with cimetidine, oestrog.lev.of OC’s signific.decr., plasma   zole/ blonanserin/dihydroergotamine/ ergonovine/ ergotamine/
   Side effects: Bld.dyscras., headache, fatig., revers. neurologic.  conc.of methadone decr.  methylergnovine/ cisapride/ St Johns Wort/lovastatin/simvas-
   reacts.incl.dizzin./tremor/ convuls. /coma, GI disturbs., ac.ren.fail.,   tatin/ salmeterol/pimozide& sildenafil (when used for treatm. of
   hepatit., jaund., liv.enzym./bilirub.incr., hair loss, hypersens. reacts.  NEVIVIR, (Activo) Bliss [P/S]  PAH), co-admin.of alprazolam, clorazepate, diazepam, estazolam,
   incl.dyspn./anaphylax.       Nevirapine                    flurazepamdos., midazolam & triazolam have potent.for extreme
   Special precautions: Sev.ren.impairm., consid. benef./risk for   Indications: In combinat.with at least 2 other antiretrov. agents for   sedat. & ser.resp.depress. and hence should not be co-admin.,
   use in pregn.& lactat., maint. adeq.hydrat.dur.high dos., elderly.  HIV-1 infect., to reduc.risk of intrapart.transmiss. of HIV-1 from moth.  dos.&gt;1 g/day of clarithromycin.
   Drug interactions: Decr.ren.clear.with probenecid.  to child in pregn. Women not tak.antiretrovir.ther.at time of labour  Side effects: V.common: Anorex., hyperlipaem., weight loss,
                                (S4) TABS, 43/20.2.8/0230     anx., insomn., circumor.& periph. paresthes., headache, taste perv-
   MYLAN VALACICLOVIR, Mylan [P/S]  717003-001, 200 mg, 60, R288,94  ers., incr.cough, abdom.pain, diarrh., N&V, maculopapul.rash, pru-
   Valaciclovir                 Dosage:
   Indications: Herpes zoster (shingles), recurr.genit. herpes.in im-  Treatm.of HIV-1 infect: Adhere strict.to dos.dur. 14 day lead-in   rit., rash, sweat., myalg., asthen. Common: Pharyngit., allergic
                                                              reacts., avitaminos., cachex., dehydrat., oed., glycosur., gout, hy-
   munocompet.adult pts., prevent./ suppress.of recurr.H.simplex in-  period to reduc.freq.of skin rash. Monit. clinic. chem. incl.LFT prior
   fect.of skin & ano-genit. mucous membr., CMV infect.prophylax.,   to & at interv. dur. ther. Follow.recomm.dos.& monit.of other con-  percholesterolaem., periph.oed., redistribut./ accumul. of body fat,
                                                              agitat., confus., depress., emot.lability, euphor., hallucinate., decr.
   CMV dis. & other herpes vir.infect.prophylax. aft. organ transpl.   com. antiretrovir.ther.
   in spec.risk cases.          Adults: Init 200 mg dly.x14 days (i.e. lead-in period) follow.by 200 mg   libido, nervousn., personality disord., abnorm.think., dizzin., hyper-
                                                              aesthaes., paraesthes., somnol., abnorm.vis., amblyopia/blurr.vis.,
   (S4) TABS. 45/20.2.8/0605    2xdly.in combinat.with at least two antiretrov.agents to which pt.not
   720818-001: 500 mg, 10, R196,58  prev. expos. to. Tot.dly.dos.not to exceed 400 mg. Pts. interrupt dos.  blepharit., diplop., eye pain, iritis, photophobia, uveitis, haemorrh.,
   720818-003: 500 mg, 42, R825,70  for &gt; 7 days should restart ther.with recommend lead-in per.  hypotens., migraine, periph.vasc. disord., postur. hypotens., tachy-
   Dosage: Adults: Herpes zoster: 1 000 mg 3x/dly for 7 days.  To reduc. risk of intrapart.transmiss. of HIV-1 from moth.to   card., dry mouth, dyspeps., eructat., flatul., loc.throat irritat., mouth
   Recurr.genit.herpes: Immunocompet.pts: 500 mg 2x/day   child: 200 mg to mother dur.labour as sngle. oral dos. pref.&gt;2 hrs.  ulc., cholangit., hepatit., hepatomeg., liv.damage, acne, cont.der-
   x5 days start.as early as poss. Init. within 24 hrs.of S&S onset./  bef.deliv.and a sngle oral dos. of 2mg/kg to infnt.&lt;48 - 72 hrs.aft.  matit., dry skin, eczema, fac.oed., folliculit., molluscum contagio-
   dur.prodromal.per.           birth /bef. disch.            sum, photosens., psoriasis, seborrh., urticar., vesiculobull. rash.,
   Prevent./suppress.of recurr.H.Simplex: Immunocompet. pts:   Contraindications: Sev.hepat.impairm., Child-Pugh class B or   arthalg., arthros., back./fac./neck pain, joint disord., musc. cramps/
   500 mg once dly. Admin. 250 mg 2x dly.if more than 10 episod.oc-  C, end-stage ren.fail.when pts.not haemodialys., do not admin./  weakn., myosit., neck rigid., twitch., dysur., haematur., kidn.calcul./
   cur/yr. Immunocomprom. pts: 500 mg 2xdly.  re-admin.to pts.with pre-treatm./ treatm.AST/ALT&gt;5 x ULN, not to   fail./pain, noctur., polyur., pyelonephrit., urethrit, urin.freq./ retent.,
   CMV infect.prophylax: Adults & adolesc. 12 yrs. & old: Init.  be re-introduc.in cases of perman.discont.for sev.rash /rash with   fev., pain, abnorm. LFT, vasodilat., Uncommon: Anaem., ecchymos.,
   ther.as soon as poss.        constitut.sympts./hypersens.syndr./ clinic. hepatit., AST/ALT&gt;   leukopen., lymphadenopathy, lymphocytes., thrombocytopen., diab.
   Post-transpl: 2 000 mg 4xdly for usual.x90 days. Poss.extend.  5x ULN dur.ther.& had rapid recurr.of liv.funct.abnormalit.on re-  mellit., abnorm.dreams, amnes., aphas., atax., convuls., grand mal
   in high-risk pts.            admin., safety in pregn.& lactat.not est., concom. ketoconazole/   convuls., inco-ordinat., neuralg., neuropathy, paralys., parosm., pe-
   Contra-indications: Acyclovir hypersens., safety in pregn.& lactat.  Rifampicin/St. John’s Wort., safety & effic. not est.in neonat.with   riph.& sensory neuropathy, taste loss, trem., vis.field defect, ear
   not est., no data avail.for childr.  birth weight &lt; 2 500g  pain, hear.impairm., incr.cerumen, tinnit., vertigo, palpit., syncope,
   Side-effects: Bld.dyscras., hypersens.reacts.incl. anaphylax./   Side effects: Sev.& life threaten.skin reacts.incl. Stev. John.  asthma, dyspnoea, epistax., hypoventilat., interstit. pneum., lung
   angioed., psych.disords.incl.mania, CNS effs., headache, dizzin.,   syndr.& tox.epiderm.necrolys., hypersens. syndr.charact.by rash   disord., rhinit., enlarg.abdom., abnorm.stools, bld. diarrh., cheilit.,
   fatig., atax., coma, confus., vis.abnormal., tachycard., hypertens.,   with constitut. sympts., sev./life threaten.hepatotox.incl.fatal   colit., constipat., dysphag., oesophagit., gastrit., gastroenterit., GI
   GI disturbs., hepatit., jaund., abnorm.LFT, skin reacts. incl.erythema   fulmin. hepatit., somnol., bld.dyscras., allerg. reacts. incl.anaphy-  disord.& haemorrh., gingivit., ileit., oral monilias., pancreatit., peri-
   multiforme/tox.epiderm. necrolys./ Stev. Johns.syndr., photosens.,   lax., headache, GI disturbs., myalg., arthralg., fatig., fev., abnorm.  odont.abscess, rect.disord., tenesmus, thirst, impot., penis disord.,
   alopec., arthralg., ren.insuff., ac.ren.fail., dysmenorrh.  LFT., ren. dysfunct  abnorm. gait, chest pain, chills, flu syndr., malaise., substern. chest
   Warnings and special precautions: Foet. abnormal. report.in   Warnings and special precautions: Monit.liv. test.more freq. if   pain, abnorm.electro-oculogram/-electroretinogram, alter.horm.lev.,
   rats, thrombot./ thrombocytopen. purpura/haemolyt.uraem.syndr.   AST/ALT&gt;2,5xULN bef./dur. treatm., critic.to monit.1  18 wks.to iden-  acciden.inj., hypotherm. Post market: Seiz., dehydrat.assoc. with
                                                      st
   poss. result.in death report. in pts.with advanc. HIV dis./aft.bone   tify sev. life-threaten.skin reacts./hepatit.or hepat.fail., discont. ther.  GI sympts./orthostat.hypotens.& ren.insuffic., MI, menorrhag., incr.
   marr.& ren.transpl., elderly, ren. funct. impairm., underly.ren.dis.,   creatin phosphokin./-triglycer. /-amylase/ -uric acid/- lactat.dehy-
   potent.nephrotox. meds., maint.adeq.hydrat., discont.ther.if CNS ad-  if sev.rash/rash accompan.by constitut. find.exper., no dos.escalat.if   drog., incr.& decr. electrol.& gluc., bld.dyscras.
                                any rash occurs dur.lead-in dos.per.until rash resolv., perform immed.
   verse reacts.occur, concom.meds.compet.with acyclovir for eliminat.   Warnings and special precautions: Pre-exist. liv. dis./ liv.en-
   potent.incr.plasma lev.of one/both meds., signif.no data on effic.if   LFT if nevirapine assoc.rash suspect., perman.discont.if mod.to sev.  zym.abnormal/hepatit., potent. allerg. reacts., discont.if pancreatit.
                                LFT abnorm. detect./hypersens.syndr.plus.viscer. involvem. occurs/
   init.more than 24 hrs.aft. S&S onset in recurr.genit.herpes., concom.  diagnos., new onset/ exacerbat.of pre-exist.diabet.mellit., hyper-
   other meds.aff.ren. physiol.  clinic.hepatit.occurs, incr.AST/ ALT lev.&/chron.hepatit.B&C co-in-  glycaem., diabet.ketoacidos., system. corticoster. eff.incl.Cushing’s
   Drug interactions: Cimetidine & probenec.decr. ren.excret./incr.  fect.assoc.with great. risk of hepat.adverse events dur.antiretrovir.   syndr.& adren. suppress. with concom.inhal./intranas.glucocortic.
   AUC , plasma AUC’s of aciclovir & mycophenolate mofetil both incr.  ther. contain.nevirapine, interrupt.ther.in case of mod. abnorm.liv.  incl. fluticasone., incr.assoc.advers.events with concom. PDE5 in-
   when admin. concom.          funct.tests & only re-introduc.at init. dos.once tests return to base-  hibits./HMG-CoA reduct.inhibits., poss. loss of therap.eff.& resist.
                                line, resist.virus emerg.with monother.theref.always admin.as com-  with concom.St. John’s Wort, contin.admin.follow.loss of vir. sup-
   NEVIR, Emcure [P/S]          binat. ther., careful monit.of pts.pre-treatm., adeq. contracept.other   press. may incr cross.resist.to other proteas. inhibits., underly.struct.
   Nevirapine                   than hormon.in women, women at high.risk of develop.rash/hepat.   heart dis.& pre-exist. conduct. syst.abnormal./concom.meds.pro-
   Indications: In combinat.with at least 2 other antiretrov. agents   adv. effs., monit.liv.funct.prior to & at interv.dur.ther.& vigil. for pro-  long.PR interv.,through CV risk assessm.with evid.of lipodystrophy,
   for HIV-I infect.            drom.signs of hepatit., opportunist. infects. & other complicat.of HIV   pts.advis.to seek med.advice if joint aches/ pains/stiffn.or diffic.in
   (S4) TABS, 42/20.2.8/0661    infect.may contin., concom.fluconazole, monit.prothromb. time with   movem.exper., opportunist. infect.risk, transmiss.of HIV to others
   717492-001: 200 mg, 60, R273,18  concom.warfar.as coagulat.time may incr./ decr., alt.ther.to clarithro-  through sex.contact.not prevent., poss.alterat.in triglyceride./ALT/
   Dosage: Adhere strict.to dos.dur.14 day lead-in period to reduc.  mycin recom.in Mycobacterium avium-intracellular complex., monit.   AST/ GGT/ CPK/uric acid & approp. lab.test.to be perform. prior
   freq.of skin rash. Monit.clinic. chem. incl.LFT prior to & at interv.dur.  methadone-maintain.pts.at start of ther.for evid.of withdraw.& adj.  to init.ther.& at period.interv./if clin. S&S occur dur.ther., report
   ther. Follow. recomm.dos.& monit.of other concom. antiretrovir. ther.  methadone dos.accord.  incr. bleed.in haemophilia type A & B treat.with protease inhibit.,
   Adults: Init 200 mg dly.x14 days (i.e. lead-in period) follow.by 200 mg   Interactions: Low.plasma conc.of concom. meds. metabol.by CY-  perform triglycer.& cholester. test.prior to & dur.ther., due to solut.
   2xdly.in combinat.with at least two antiretrov.agents to which pt.not   P3A or CYP2B enzymes, saquinavir (hard gelatine caps)/indinavir   ethanol content of sol.& soft gel caps concom.disulfiram/ drugs with
   prev. expos. to. Tot.dly.dos.not to exceed 400 mg.  AUC reduc., lopinavir AUC, Cmax& Cmin decr., incr.plasma lev.with   disulfiram-like reacts.to be avoid., separate didanosine & ritonavir
   Contraindications: Sev.hepat.impairm., Child-Pugh class B or C,   ketoconazole, nevirapine expos.incr.with concom. fluconazole, AUC,   admin.by 2,5 hrs., concom. ketoconazole.
   end-stage ren.fail.when pts.not haemodialys., AST/ALT &gt;5x upper   C max& C min signific.low.by rifampicin, rifabutin conc.incr., hypericum   Interactions: Agents which incr.CYP3A activ. e.g.phenobarbital,
   lev.of normality (ULN) until baseline AST/ALT stabilis. &lt;5 ULN, not to   perforatum (St John’s Wort) decr.conc.& result. sub-optimal lev.,   carbamazepine, dexamethasone, phenytoin, rifampin & rifabutin
   be re-introduc.in cases of perman.discont.for sev. rash/rash with con-  elev.trough conc.with cimetidine, oestrog. lev.of OC’s signific.decr.,   decr. ritonavir plasma conc., therapeut.eff.of direct. glucuronidated
   stitut.sympts./hypersens. syndr./ clinic.hepatit., AST/ALT&gt; 5x ULN   plasma conc.of methadone decr.  agents lost, dos.reduct. poss. for those agents extens.metabol.by
   dur.ther.& had rapid recurr.of liv.funct.abnormalit.on re-admin., safety   CYP3A, card. & neurolog.events with disopyram./mexilet./ nefazo-
   in pregn.& lactat. not est., concom. ketoconazole & St. John’s Wort.  NORVIR, Abbvie [P/S] &  done/ fluoxet., desipramine AUC incr., didanosine C max & AUC reduc.,
   Side effects: Sev.& life threaten.skin reacts. incl. Stev.John.syndr.&   Ritonavir.  ketoconazole mean-half life incr., AUC of sulfamethoxazole reduc.
   tox.epiderm.necrolys., hypersens. syndr.charact.by rash with consti-  Indications: Pharmacokinet.enhanc.of cert.other antiretrovir.  and of trimethoprim incr., mean C max & AUC of ethinyl oestradiol re-
   tut. sympts., sev./life threaten.hepatotox.incl.fatal fulmin. hepatit.,   protease inhibit.  duc., AUC of theophylline decr., plasma conc.decr.with concom.St
   somnol., bld.dyscras., allerg. reacts. incl.anaphylax., headache, GI   (S4) SOL, [P/S] 31/20.2.8/0217.  John’s Wort, alprazolam C max decr., amprenavir/indinavir/ digoxin/
   disturbs., myalg., arthralg., fatig., fev., abnorm.LFT.  838527-035: 80 mg/ml, 1x90 ml, R83,82  nelfinavir/rifabutin/saquinavir/ sildenafil/ tadalafil/ vardenafil/tra-
                    st
   Special precautions: Critic.to monit.1  18 wks. to identify sev.  (S4) TAB, [P/S] 44/20.2.8/0128.  zodone/vincristine/ vinblastine/ fluticasone propionate conc. incr.,
   life-threaten.skin reacts./hepatit.or hepat. fail., discont.ther.if sev.  721595-001: 100 mg, 60, R70,13  bosentan C max & AUC incr., bupropion lev.decr., buspirone lev.elev.,
   rash/rash accompan. by constitut.find.exper., perman. discont. if   (S4) ORAL POWD, [P/S] 51/20.2.8/0154.  clarithromyc.metabol.inhibit., ritonavir C max & AUC incr.by delavirdine,
   mod.to sev.LFT abnorm.detect./ hypersens.syndr.occurs, incr.AST/  3000740-001: 100 mg, 30 sach.+mix.cup and syr., R50,34  AUC incr. with concom. efavirenz & efavirenz AUC incr., fusidic acid &
   ALT lev.&/ chron. hepatit.B&C co-infect.assoc.with great.risk of   Dosage: Admin.with food. Reconstit.powd.to be consum.within 2   ritonavir conc.incr.if admin.concom., methadone/ warfarin conc.decr.,
   hepat.adverse events dur.antiretrovir.ther. contain. nevirapine, inter-  hrs. Sprinkle powd.eith on soft food/mix.with suit.liq. For powd.dos.  voriconazole AUC decr., zidovudine AUC/C max decr., tobacco decr AUC
   rupt.ther.in case of mod. abnorm. liv.funct.tests & only re-introduc.  of less than 100 mg mix sach.with 9,4 ml liq & admin.with dos.syr.
   at init. dos. once tests return to baseline, resist.virus emerg. with   Adults: When used as pharmacokinet.enhanc.for anoth.antiretrovir.  NUVACO, AI Pharm Ltd [P/S]
   monother.theref.always admin.as combinat. ther., careful monit.  protease inhibit.the PI of partic. protease inhibir.should be consulted.  Tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg, dolute-
   of pts.pre-treatm., adeq. contracept.other than hormon.in women,   Paediatric Patients: Use in combinat.with other antiretrovir.  gravir sod.50 mg
   women at high.risk of develop.rash, monit.liv. funct. prior to & at   agents. Recomm.dos: 400 mg/m  of body surf.area 2xdly.not   Indications: Treatm.of HIV infect.adults ≥ 18 yrs.
                                                2
   interv.dur.ther.& vigil.for prodrom. signs of hepatit., opportunist.in-  exceed.600 mg 2x/dly. Start at 250 mg/m  and incr.at 2-3 day in-  (S4) TABS, 52/20.2.8/0949
                                                  2
   fects.& other complicat.of HIV infect.may contin., concom. flucona-  terv. by 50 mg/m  2xdly. Use highest tolerat.dose for maint.ther.  3000585-001: 30, R494,00
                                        2</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page310.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>&nbsp;&nbsp;&nbsp;<a href="page309.html">309</a>&nbsp;&nbsp;&nbsp;<a href="page310.html">310</a>&nbsp;&nbsp;&nbsp;<a href="page311.html">311</a>&nbsp;&nbsp;&nbsp;<a href="page312.html">312</a>&nbsp;&nbsp;&nbsp;<a href="page313.html">313</a>&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>
             </td>
             <td width="35%"><a href="page312.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page312.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
